Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized studyChristina Fotopoulou, Hani Gabra, Ignace Vergote et al.|Annals of Oncology|2013Cited by 38
8004 ORAL Safety and Efficacy Outcomes in Heavily and Non-heavily Pretreated Patients With Recurrent Ovarian Cancer (ROC) After Single-agent Trabectedin Treatment – Pooled Analysis of Phase II TrialsNicoletta Colombo, Antonio González-Martı́n, Mariusz Bidziński et al.|European Journal of Cancer|2011Cited by 2